1
|
Sumi S. Regenerative medicine for insulin deficiency: creation of pancreatic islets and bioartificial pancreas. JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES 2011; 18:6-12. [PMID: 20589399 DOI: 10.1007/s00534-010-0303-3] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
Recent advances in pancreas organogenesis have greatly improved the understanding of cell lineage from inner cell mass to fully differentiated β-cells. Based upon such knowledge, insulin-producing cells similar to β-cells to a certain extent have been generated from various cell sources including embryonic stem cells (ESCs) and induced pluripotent stem (iPS) cells, although fully differentiated cells comparable to β-cells are not yet available. The bioartificial pancreas is a therapeutic approach to enable allo- and xenotransplantation of islets without immune suppression. Among several types of bioartificial pancreases (BAPs), micro-encapsulated porcine islets are already in use in clinical trials and may, perhaps, replace islet transplantation in the near future. Some types of bioartificial pancreas such as macro-encapsulation are also useful for keeping transplanted cells enclosed in case retrieval is necessary. Therefore, early clinical applications of artificially generated β-like cells, especially those from ESCs or iPS cells, will be considered in combination with retrievable BAPs.
Collapse
Affiliation(s)
- Shoichiro Sumi
- Institute for Frontier Medical Sciences, Kyoto University, Kyoto, Japan.
| |
Collapse
|
2
|
Vicente-Salar N, Santana A, Reig JA, Roche E. Differentiation of Embryonic Stem Cells Using Pancreatic Bud-Conditioned Medium Gives Rise to Neuroectoderm-Derived Insulin-Secreting Cells. Cell Reprogram 2011; 13:77-84. [DOI: 10.1089/cell.2010.0054] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Nestor Vicente-Salar
- Research Foundation of Alicante Universitary General Hospital, Hepatology Unit, Alicante, Spain
| | - Alfredo Santana
- Research Unit, Gran Canaria Hospital Dr. Negrin and Genetic Unit, Childhood Hospital Complex, Las Palmas, Canary Islands, Spain
| | - Juan A. Reig
- Institute of Bioengineering, University Miguel Hernandez, Elche, Spain
| | - Enrique Roche
- Institute of Bioengineering, University Miguel Hernandez, Elche, Spain
| |
Collapse
|
3
|
Sordi V, Bertuzzi F, Piemonti L. Diabetes mellitus: an opportunity for therapy with stem cells? Regen Med 2008; 3:377-97. [PMID: 18462060 DOI: 10.2217/17460751.3.3.377] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
In both Type 1 and 2 diabetes, insufficient numbers of insulin-producing beta-cells are a major cause of defective control of blood glucose and its complications. Restoration of damaged beta-cells by endocrine pancreas regeneration would be an ideal therapeutic option. The possibility of generating insulin-secreting cells with adult pancreatic stem or progenitor cells has been investigated extensively. The conversion of differentiated cells such as hepatocytes into beta-cells is being attempted using molecular insights into the transcriptional make-up of beta-cells. Additionally, the enhanced proliferation of beta-cells in vivo or in vitro is being pursued as a strategy for regenerative medicine for diabetes. Advances have also been made in directing the differentiation of embryonic stem cells into beta-cells. Although progress is encouraging, major gaps in our understanding of developmental biology of the pancreas and adult beta-cell dynamics remain to be bridged before a therapeutic application is made possible.
Collapse
Affiliation(s)
- Valeria Sordi
- Laboratory of Experimental Surgery, San Raffaele Scientific Institute, via Olgettina 60, 20132 Milan, Italy
| | | | | |
Collapse
|
4
|
Abstract
Type 1 diabetes mellitus (T1DM) is a disease that results from the selective autoimmune destruction of insulin-producing beta-cells. This disease process lends itself to cellular therapy because of the single cell nature of insulin production. Murine models have provided opportunities for the study of cellular therapies for the treatment of diabetes, including the investigation of islet transplantation, and also the possibility of stem cell therapies and islet regeneration. Studies in islet transplantation have included both allo- and xeno-transplantation and have allowed for the study of new approaches for the reversal of autoimmunity and achieving immune tolerance. Stem cells from hematopoietic sources such as bone marrow and fetal cord blood, as well as from the pancreas, intestine, liver, and spleen promise either new sources of islets or may function as stimulators of islet regeneration. This review will summarize the various cellular interventions investigated as potential treatments of T1DM.
Collapse
Affiliation(s)
- D D Lee
- Section of Transplantation, Department of Surgery, The University of Chicago, IL 60637, USA
| | | | | |
Collapse
|
5
|
Embryonic stem cell therapy for diabetes mellitus. Semin Cell Dev Biol 2007; 18:827-38. [DOI: 10.1016/j.semcdb.2007.09.009] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2007] [Accepted: 09/06/2007] [Indexed: 12/20/2022]
|
6
|
McKiernan E, O'Driscoll L, Kasper M, Barron N, O'Sullivan F, Clynes M. Directed Differentiation of Mouse Embryonic Stem Cells into Pancreatic-Like or Neuronal- and Glial-Like Phenotypes. ACTA ACUST UNITED AC 2007; 13:2419-30. [PMID: 17655486 DOI: 10.1089/ten.2006.0373] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The derivation of definitive endoderm and in particular endocrine cell types from undifferentiated embryonic stem (ES) cells remains difficult to achieve. In this study, we investigated the potential to regulate the differentiation of ES cells into endodermal derivatives using extracellular factors previously associated with various aspects of pancreatic development. Feeder-free-cultured mouse ESD3 cells were manipulated to form embryoid bodies (EBs) in the presence of retinoic acid (RA). RA-treated EBs were subsequently exposed to sodium butyrate (SB), betacellulin (BTC) or activin A (AA). A comparative analysis was performed on these models of directed differentiation in parallel with a model of spontaneous differentiation. Lineage differentiation was determined by profiling multilineage marker transcript expression (neuronal, myogenic, exocrine and endocrine pancreas, extraembryonic and apoptotic) and subsequent protein expression within ES-derived cultures. Using a two-stage differentiation protocol developed during this study, we successfully demonstrated the derivation of an intermediate multipotential population (RA_EBs) from undifferentiated ES cells that preferentially gives rise to pancreatic endocrine insulin-expressing cell types in the presence of SB, and neuronal- and glial-like cell types in the presence of AA or BTC.
Collapse
Affiliation(s)
- Eadaoin McKiernan
- National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland
| | | | | | | | | | | |
Collapse
|
7
|
Lü P, Liu F, Yan L, Peng T, Liu T, Yao Z, Wang CY. Stem cells therapy for type 1 diabetes. Diabetes Res Clin Pract 2007; 78:1-7. [PMID: 17349714 DOI: 10.1016/j.diabres.2007.02.003] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/28/2006] [Revised: 01/10/2007] [Accepted: 02/02/2007] [Indexed: 11/30/2022]
Abstract
In this article, we have reviewed the developments of studies of stem cells therapy for type 1 diabetes since this century. Review of the literature was based on computer searches (PubMed) and our studies. Type 1 diabetes can now be ameliorated by islet transplantation, but this treatment is restricted by the scarcity of islet tissue. Hopes for a limitless supply of a substitute for primary islets of Langerhans and progress in stem cell biology have led to research into the feasibility of stem/progenitor cells to generate insulin-producing cells to use in replacement therapies for diabetes. An increasing body of evidence indicated that, in addition to embryonic stem cells, several potential adult stem/progenitor cells, derived from pancreas, liver, spleen, and bone marrow could differentiate into insulin-producing cells in vitro or in vivo. However, significant controversy currently exists in this field. Moreover, safe suppression of autoimmunity or specific tolerance to auto-antigens for patients with type 1 diabetes must be achieved before this promising new technology can lead to a great progress in clinical practice. To prevent type 1 diabetes through genetic engineering of hematopoietic stem cells represents another new strategy. Much basic research is still required.
Collapse
Affiliation(s)
- Ping Lü
- Department of General Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China.
| | | | | | | | | | | | | |
Collapse
|
8
|
Mc Kiernan E, Barron NW, O'Sullivan F, Barham P, Clynes M, O'Driscoll L. Detecting de novo insulin synthesis in embryonic stem cell-derived populations. Exp Cell Res 2006; 313:1405-14. [PMID: 17362926 DOI: 10.1016/j.yexcr.2006.12.013] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2006] [Revised: 11/28/2006] [Accepted: 12/19/2006] [Indexed: 11/24/2022]
Abstract
Several studies in recent years have described protocols, both genetic- and culture-based, that induce the differentiation of embryonic stem (ES) cells towards a pancreatic beta-cell type. The success of previous protocols in generating insulin-producing beta-cells has been questioned due in part to uncertainty regarding cell lineage but also due to the controversy regarding the source of any insulin detected in these cells. In an attempt to address the latter, we designed a novel assay that can identify de novo insulin synthesis. The method is based on metabolic labeling combined with a modified radio-immunoassay and will routinely detect less than 5 pg/microl of de novo insulin synthesis in lysates from the insulinoma cell line MIN6. This assay failed to detect any newly translated insulin in an ES cell-derived population generated using an adapted version of a previously published, 5-stage differentiation protocol. In combination with other techniques, including immunofluorescent staining and western blot analysis to detect and quantify C-peptide, we conclude that the majority of the insulin found in these differentiated ES cell cultures is medium-derived.
Collapse
Affiliation(s)
- Eadaoin Mc Kiernan
- National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
| | | | | | | | | | | |
Collapse
|
9
|
Ensenat-Waser R, Santana A, Paredes B, Zenke M, Reig JA, Roche E. Embryonic Stem Cell Processing in Obtaining Insulin-Producing Cells: A Technical Review. ACTA ACUST UNITED AC 2006. [DOI: 10.1089/cpt.2006.9997] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Affiliation(s)
- Roberto Ensenat-Waser
- Institute for Biomedical Engineering–Cell Biology, University Medical School/Rheinisch-Westfälische Technische Hochschule Aachen, Aachen, Germany
| | - Alfredo Santana
- Genetic and Cytogenetic Unit, Childhood Hospital of Canary Islands, Las Palmas, Spain
| | - Beatriz Paredes
- Institute of Bioengineering, University Miguel Hernandez, Alicante, Spain
| | - Martin Zenke
- Institute for Biomedical Engineering–Cell Biology, University Medical School/Rheinisch-Westfälische Technische Hochschule Aachen, Aachen, Germany
| | - Juan Antonio Reig
- Institute of Bioengineering, University Miguel Hernandez, Alicante, Spain
| | - Enrique Roche
- Institute of Bioengineering, University Miguel Hernandez, Alicante, Spain
| |
Collapse
|
10
|
Marenah L, McCluskey JT, Abdel-Wahab YHA, O'Harte FPM, McClenaghan NH, Flatt PR. A stable analogue of glucose-dependent insulinotropic polypeptide, GIP(LysPAL16), enhances functional differentiation of mouse embryonic stem cells into cells expressing islet-specific genes and hormones. Biol Chem 2006; 387:941-7. [PMID: 16913844 DOI: 10.1515/bc.2006.118] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Embryonic stem (ES) cells can be differentiated into insulin-producing cells by conditioning the culture media. However, the number of insulin-expressing cells and amount of insulin released is very low. Glucose-dependent insulinotropic polypeptide (GIP) enhances the growth and differentiation of pancreatic beta-cells. This study examined the potential of the stable analogue GIP(LysPAL16) to enhance the differentiation of mouse ES cells into insulin-producing cells using a five-stage culturing strategy. Semi-quantitative PCR indicated mRNA expression of islet development markers (nestin, Pdx1, Nkx6.1, Oct4), mature pancreatic beta-cell markers (insulin, glucagon, Glut2, Sur1, Kir6.1) and the GIP receptor gene GIP-R in undifferentiated (stage 1) cells, with increasing levels in differentiated stages 4 and 5. IAPP and somatostatin genes were only expressed in differentiated stages. Immunohistochemical studies confirmed the presence of insulin, glucagon, somatostatin and IAPP in differentiated ES cells. After supplementation with GIP(LysPAL16), ES cells at stage 4 released insulin in response to secretagogues and glucose in a concentration-dependent manner, with 35-100% increases in insulin release. Cellular C-peptide content also increased by 45% at stages 4 and 5. We conclude that the stable GIP analogue enhanced differentiation of mouse ES cells towards a phenotype expressing specific beta-cell genes and releasing insulin.
Collapse
Affiliation(s)
- Lamin Marenah
- School of Biomedical Sciences, University of Ulster, Coleraine BT52 1SA, Northern Ireland, UK
| | | | | | | | | | | |
Collapse
|
11
|
Roche E, Jones J, Arribas MI, Leon-Quinto T, Soria B. Role of small bioorganic molecules in stem cell differentiation to insulin-producing cells. Bioorg Med Chem 2006; 14:6466-74. [PMID: 16797999 DOI: 10.1016/j.bmc.2006.06.015] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2006] [Revised: 06/06/2006] [Accepted: 06/08/2006] [Indexed: 01/10/2023]
Abstract
The use of small specific molecules has been instrumental in the modulation of stem cell proliferation and differentiation to obtain insulin-containing cells. Examples include nutrients (glucose, nicotinamide and retinoic acid), acids (butyrate), alkaloids (cyclopamine and conophylline) and pharmacological agents (LY294002 and wortmannin). These molecules, alone or in combination with specific growth factors and hormones, will likely provide key information to design specific culture media in order to obtain customized cells for implantation in diabetes. In addition, the study of such molecules will help to understand the mechanisms involved in stem cell biology as well as contribute to the design of specific drugs for islet repair and regeneration in diabetes.
Collapse
Affiliation(s)
- Enrique Roche
- Institute of Bioengineering, University Miguel Hernández, San Juan, Alicante, Spain.
| | | | | | | | | |
Collapse
|
12
|
Rippon HJ, Polak JM, Qin M, Bishop AE. Derivation of Distal Lung Epithelial Progenitors from Murine Embryonic Stem Cells Using a Novel Three-Step Differentiation Protocol. Stem Cells 2006; 24:1389-98. [PMID: 16456134 DOI: 10.1634/stemcells.2005-0465] [Citation(s) in RCA: 107] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Embryonic stem cells (ESCs) are a potential source for the cell-based therapy of a wide variety of lung diseases for which the only current treatment is transplantation. However, distal lung epithelium, like many other endodermally derived somatic cell lineages, is proving difficult to obtain from both murine and human ESCs. We have previously obtained alveolar epithelium from ESCs, although final cell yield remained extremely low. Here, we present an optimized three-step protocol for the derivation of distal lung epithelial cells from murine ESCs. This protocol incorporates (a) treatment of early differentiating embryoid bodies with activin A to enhance the specification of the endodermal germ layer, followed by (b) adherent culture in serum-free medium and (c) the final application of a commercial, lung-specific medium. As well as enhancing the specification of distal lung epithelium, this protocol was found to yield cells with a phenotype most closely resembling that of lung-committed progenitor cells present in the foregut endoderm and the early lung buds during embryonic development. This is in contrast to our previous differentiation method, which drives differentiation through to mature type II alveolar epithelial cells. The derivation of a committed lung progenitor cell type from ESCs is particularly significant for regenerative medicine because the therapeutic implantation of progenitor cells has several clear advantages over the transplantation of mature, terminally differentiated somatic cells.
Collapse
Affiliation(s)
- Helen J Rippon
- Tissue Engineering & Regenerative Medicine Centre, Imperial College London, Chelsea & Westminster Campus, London SW10 9NH, UK
| | | | | | | |
Collapse
|
13
|
Abstract
Pancreatic islet transplantation represents an attractive approach for the treatment of diabetes. However, the limited availability of donor islets has largely hampered this approach. In this respect, the use of alternative sources of islets such as the ex vivo expansion and differentiation of functional endocrine cells for treating diabetes has become the major focus of diabetes research. Adult pancreatic stem cells /progenitor cells have yet to be recognized because limited markers exist for their identification. While the pancreas has the capacity to regenerate under certain circumstances, questions where adult pancreatic stem/progenitor cells are localized, how they are regulated, and even if the pancreas harbors a stem cell population need to be resolved. In this article, we review the recent achievements both in the identification as well as in the expansion of pancreatic stem/progenitor cells.
Collapse
Affiliation(s)
- You-Qing Zhang
- Department of Immunology, The Scripps Research Institute, La Jolla, CA, 92037, USA.
| | | | | |
Collapse
|
14
|
Abstract
Clinical islet transplantation trials based on cadaveric allogenic islets have demonstrated that it is indeed possible to restore near-physiological insulin secretion capacity in a type 1 diabetic patient through transplantation of insulin-producing cells. In order to develop this form of therapy to become available for the vast majority of patients with diabetes, new sources of transplantable insulin-producing cells need to be identified. Stem cells provide the best potential to achieve this goal. Controversial results have been presented concerning the existence and nature of pancreatic islet stem or precursor cells. An increasing body of evidence suggests that the pancreatic and hepatic cell types (hepatocytes, islet, acinar and ductal cells) have remarkable plasticity and can de- and trans-differentiate into each other under appropriate conditions. Elucidation of the molecular mechanisms regulating these processes could lead to clinically applicable ways of either inducing pancreatic islet regeneration in situ or to expanding the insulin-producing cells in vitro for transplantation. The emergence of human embryonic stem cells has led to an active area of research aiming to achieve targeted differentiation of these cells into a safely transplantable beta-like cell. After initial excitement, it appears that much basic research is still required before this goal could be achieved.
Collapse
Affiliation(s)
- Timo Otonkoski
- Hospital for Children and Adolescents, University of Helsinki, Finland.
| | | | | |
Collapse
|